Trilogy Capital Inc. Sells 3,850 Shares of Astera Labs, Inc. $ALAB

Trilogy Capital Inc. cut its stake in shares of Astera Labs, Inc. (NASDAQ:ALAB) by 58.3% in the 2nd quarter, HoldingsChannel reports. The fund owned 2,750 shares of the company’s stock after selling 3,850 shares during the quarter. Trilogy Capital Inc.’s holdings in Astera Labs were worth $1,328,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently modified their holdings of ALAB. Reflection Asset Management bought a new stake in Astera Labs in the 4th quarter valued at about $25,000. CX Institutional grew its position in Astera Labs by 1,330.8% in the second quarter. CX Institutional now owns 186 shares of the company’s stock valued at $90,000 after acquiring an additional 173 shares during the last quarter. Smartleaf Asset Management LLC grew its holdings in shares of Astera Labs by 422.2% during the 4th quarter. Smartleaf Asset Management LLC now owns 188 shares of the company’s stock valued at $32,000 after purchasing an additional 152 shares during the last quarter. Towarzystwo Funduszy Inwestycyjnych PZU SA bought a new stake in shares of Astera Labs during the fourth quarter worth $33,000. Finally, Wexford Capital LP acquired a new position in Astera Labs in the 3rd quarter worth about $39,000. Institutional investors and hedge funds own 60.47% of the company’s stock.

Insider Buying and Selling

In other Astera Labs news, Director Stefan A. Dyckerhoff sold 3,505 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The stock was sold at an average price of $450.00, for a total value of $1,577,250.00. Following the completion of the transaction, the director owned 57,466 shares in the company, valued at $25,859,700. This trade represents a 5.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bethany Mayer sold 686 shares of the stock in a transaction dated Wednesday, June 24th. The stock was sold at an average price of $395.04, for a total transaction of $270,997.44. Following the completion of the sale, the director directly owned 5,550 shares in the company, valued at approximately $2,192,472. The trade was a 11.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 1,676,845 shares of company stock valued at $444,928,806. Corporate insiders own 10.40% of the company’s stock.

Astera Labs Stock Performance

NASDAQ ALAB opened at $361.67 on Wednesday. The company has a 50-day simple moving average of $361.12 and a 200 day simple moving average of $232.51. Astera Labs, Inc. has a 52-week low of $97.89 and a 52-week high of $499.48. The company has a market capitalization of $61.99 billion, a PE ratio of 244.37, a price-to-earnings-growth ratio of 3.72 and a beta of 3.84.

Astera Labs (NASDAQ:ALAB) last posted its quarterly earnings data on Tuesday, August 4th. The company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.69 by $0.11. The business had revenue of $392.40 million for the quarter, compared to the consensus estimate of $360.85 million. Astera Labs had a return on equity of 18.49% and a net margin of 26.72%.Astera Labs’s revenue for the quarter was up 104.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.44 earnings per share. Astera Labs has set its Q3 2026 guidance at 1.160-1.210 EPS. As a group, analysts forecast that Astera Labs, Inc. will post 1.86 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on ALAB. Susquehanna raised their price target on shares of Astera Labs from $230.00 to $275.00 and gave the company a “neutral” rating in a research note on Friday, July 31st. JPMorgan Chase & Co. boosted their price target on Astera Labs from $205.00 to $280.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Roth Capital reissued a “buy” rating and set a $275.00 price objective on shares of Astera Labs in a research report on Wednesday, May 6th. Evercore reissued an “outperform” rating and issued a $297.00 price target on shares of Astera Labs in a research report on Tuesday, May 19th. Finally, Morgan Stanley reiterated an “overweight” rating and set a $335.00 price target on shares of Astera Labs in a research note on Monday. Thirteen analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $289.00.

Key Astera Labs News

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Q2 earnings and revenue beat expectations. Astera Labs reported adjusted earnings of $0.80 per share, above the $0.69 consensus estimate and up from $0.44 a year earlier. Revenue reached a record $392.4 million, exceeding the $360.85 million estimate and increasing 104.5% year over year. Astera Labs Beats Q2 Earnings and Revenue Estimates
• Positive Sentiment: Q3 guidance was well above analyst forecasts. Management projected earnings of $1.16-$1.21 per share and revenue of $540 million-$560 million, compared with consensus estimates of $0.73 per share and $410.3 million in revenue. The outlook implies another sharp acceleration in growth. Astera Labs Reports Second Quarter 2026 Financial Results
• Positive Sentiment: New product ramp is expected to drive the acceleration. Astera Labs said Q3 growth will be supported by production ramp-up of its Scorpio X-Series 320-lane fabric switch, alongside diversified demand across AI fabrics and signal-conditioning products. Astera Labs Stock Shoots Higher After Q2 Earnings
• Neutral Sentiment: Investor expectations were already elevated. Recent coverage highlighted optimism surrounding Astera Labs’ Amazon partnership and AI infrastructure exposure, helping the stock advance ahead of earnings. Its high valuation and volatility mean additional upside may depend on continued results that exceed expectations. Astera Labs Benefits From Amazon Partnership
• Negative Sentiment: One analyst target remains below the current market level. A previously reported price-target increase to $275 suggests some valuation caution, although that target predates the latest earnings report and guidance. Astera Labs Price Target Raised to $275

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.